Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07077083 · ClinicalTrials.gov registry record · Phase 2
CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT07077083: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT07077083 is a Phase 2 study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07077083, a Phase 2 study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn whether 89Zr-Girentuximab PET scans can inform management of renal cell carcinoma. The main questions it aims to answer are: * Does the 89Zr-Girentuximab PET detect ccRCC that is left behind or has come back after treatment? * What differences can be seen on the 89Zr-Girentuximab PET before and after standard of care treatment? Participants in arm 1 will be given the study drug followed by a PET scan 3-7 days after injection. Participants in arm 2 will receive the same, but will proceed with their standard of care cryoablation after the initial PET scan. Within 3 days of the cryoablation treatment, participants will receive a repeat PET scan.
Interventions
- DRUG 89Zr-Girentuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-03-16 |
| Est. Completion | 2028-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07077083
The ClinicalTrials.gov registry entry for NCT07077083 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 89Zr-Girentuximab is the first listed.
NCT07077083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07077083 about?
NCT07077083 is a clinical study titled "CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC". The goal of this clinical trial is to learn whether 89Zr-Girentuximab PET scans can inform management of renal cell carcinoma. The main questions it aims to answer are: * Does the 89Zr-Girentuximab PET detect ccRCC that is left behind or has come back after treatment? * What differences can be seen...
What is the current status of trial NCT07077083?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2026-03-16. Estimated completion is 2028-08-01.
What interventions are being tested in trial NCT07077083?
The interventions under investigation include: 89Zr-Girentuximab (DRUG).
Who is sponsoring clinical trial NCT07077083?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.